Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …

Multiple myeloma (MM) is a hematologic malignancy defined by the clonal proliferation of
transformed plasma cells. Despite tremendous advances in the treatment paradigm of MM, a …

In preclinical models, anakinra, an IL-1 receptor antagonist (IL-1Ra), reduced immune
effector cell-associated neurotoxicity syndrome (ICANS) without compromising anti-CD19 …

The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly
because of the expanding indications for standard-of-care treatment and the development of …

Background T cell mediated hyperinflammatory responses such as cytokine release
syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) are …

Patients with advanced cancer generate 4 million visits annually to emergency departments
(EDs) and other dedicated, high‐acuity oncology urgent care centers. Because of both the …

With growing indications for chimeric antigen receptor (CAR) T-cell therapy, toxicity profiles
are evolving. There is an urgent and unmet need of approaches to optimally manage …

Chimeric antigen receptor T cell (CAR-T) therapies, including axicabtagene ciloleucel (axi-
cel) and tisagenlecleucel (tisa-cel), are innovative treatments for patients with relapsed or …

Chimeric antigen receptor-engineered (CAR)-T cell therapy remains limited by significant
toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated …

Chimeric antigen receptor (CAR)-T cells have emerged as a promising treatment modality
for various hematologic and solid malignancies over the past decade. Animal models …